Back

QRS-T angle is associated with sudden cardiac death risk in patients with hypertrophic cardiomyopathy

13 May 2024 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 8 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Hyemoon Chung

Kyung Hee Medical Center, Seoul (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Myocardial bridging in hypertrophic cardiomyopathy: prevalence, characteristics, and clinical implications
Doctor I. Ferreira Neves (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
One gene, the same mutation, different natural histories: the diverse odyssey of four families with hypertrophic cardiomyopathy
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Exercise echocardiography to evaluate the diastolic function in hypertrophic cardiomyopathy
Doctor D. Faro (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Clinical profile and outcomes of patients with hypertrophic cardiomyopathy associated with mutations in the MYH7 gene: a long longitudinal follow up study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Sarcomere-negative hypertrophic cardiomyopathy: clinical characteristics, management, and outcomes
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 8

The Event

Event poster

Heart Failure 2024

13 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
QRS duration as a novel prognostic ECG marker in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Overcoming sudden cardiac death and heading towards progressive heart failure: Insights from a hypertrophic cardiomyopathy referral-center cohort
thumbnail
Congress Presentation
A larger reduction of spatial mean QRS-T angle during cardiac resynchronisation therapy is associated with a lower risk of mortality and heart failure hospitalisation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources